Forty two cases of confirmed hepatitis C virus (HCV) infection with available liver histology were studied. Most patients, 23 of 42 (55%) had abnormal liver function tests but 19 of 42 (45%) had persistently normal liver transaminases (mean aspartate transaminase (AST) 24
(11%), showed non-specific reactive hepatitis in eight of 19 (42%), chronic persistent hepatitis in six of 19 (31%), and chronic active hepatitis in three of 19 (16%)). Twenty three of42 (55%) had either persistently or temporary raised liver transaminases (mean AST 96-2 IU/l, mean follow up 16 months). Histological examinations in this second group with abnormal liver biochemistry showed reactive hepatitis in five of 23 (22%), chronic persistent hepatitis in six of 23 (26%), chronic active hepatitis in 10 of 23 (43%), and cirrhosis in two (9°/). Average alcohol intake was significantly higher in the group within abnormal liver function (17.8 v 6 .4 units, p=O.Ol). Although serious pathology was more frequent in the abnormal transaminase group, significant liver pathology (chronic persistent hepatitis or chronic active hepatitis) was found in nine of 19 (47%) of cases with repeatedly normal transaminases. Liver biopsy is advised in all cases of chronic hepatitis C infection to accurately assess both the degree of fibrosis and the current activity of the disease.
The discovery of the hepatitis C virus identified this organism as the cause in the majority of cases with post-transfusion and most cases of sporadic non-A, non-B hepatitis.'-3 In addition, the subsequent widespread use of serological tests in screening blood donations and at risk populations had identified many subjects with no or minimal symptoms who are chronically infected by the hepatitis C virus (HCV).4 5 The treatment of these patients is controversial as early studies of the natural history of HCV infection were based on patients with clinically detectable disease and the overall risk of morbidity and mortality in these asymptomatic subjects therefore remains unknown.
In September 1991, screening for HCV of all volunteer blood donations commenced in the United Kingdom and a prevalence for HCV infection of around 1: 1500 was found.6-8 Many of these patients have now been referred to specialist liver clinics and provide the bulk of the HCV caseload. Most are well or have only minimal symptoms and their liver biochemistry may be normal. As studies among blood donors in Spain4 and then Italy9 found significant liver pathology in the face of normal liver biochemistry, we have routinely offered liver biopsy to all HCV infected subjects where either persistent viraemia has been shown by the polymerase chain reaction, or in whom abnormal liver function or clinical disease has been found. In this study, we have compared the histological findings in our patients with persistently normal liver function with patients in whom persistent or temporary increases in liver transaminases were detected, to find out if routine liver function can accurately reflect the liver histology, As a recent study has reported the follow up of blood donors within a UK region, we have analysed our local HCV positive donors as a subgroup,'0 to show the proportion of patients referred from the blood transfusion service that come to liver biopsy and the histological results found.
Methods
Forty two patients were identified from attendance at a gastroenterology clinic in Oxford, who were (a) positive for anti-HCV by second generation ELISA (Abbott Laboratories), (b) had at least three serial estimations of the serum aspartate transaminase (AST) ( 13 , and cirrhosis in two. Figure 1 shows histological diagnosis compared with mean AST. One of two patients with cirrhosis had a high previous alcohol intake, (x-1-antitrypsin deficiency, and features of both hepatitis C and alcohol related liver damage on biopsy (appreciable iron deposition). Only one other biopsy specimen showed features suggestive of both alcohol and hepatitis C (chronic persistent hepatitis, lymphoid follicles, and Mallory's hyaline). Many of the biopsy specimens showed features typical of hepatitis C. Fatty change was seen in 14 of 42 (33%) and was considerable in five of 42 (12%). Portal lymphoid follicles were seen in seven of 42 (17%). A mild degree of bile duct damage was seen in 16 of 42 (38%) with more severe changes in a further three of 42 (7%). Sinusoidal infiltration was common in 24 of 42 (57%). Table IV Comparison between the two groups (perflam-sistently normal or abnormal liver transamiosis). nases) identified in this study showed index differences. The length of follow up tended to was be longer in those with abnormal liver func-)f the tion. This probably reflects that some of this :tivity group had symptomatic disease and were mean identified originally as non-A, non-B hepatitis.
Also many of the normal group patients were asymptomatic and have only been diagnosed recently following the introduction of blood donor screening. Follow up of cases was curwas tailed in any patient who started treatment 26 of with interferon. Patients with abnormal liver i had function had significantly higher alcohol intake )rmal than those with normal AST activities. This nal or may merely reflect the different indications for had liver biopsy between the groups but could also had suggest an additive effect of alcohol consump-;es of tion on the liver transaminase activities in been HCV infection. Two recent studies of alcopeat-holic liver disease and HCV infection conre for firmed by HCV RNA detection have further three examined this relation. ' Chronic persistent hepatitis 6 6 12 Chronic active hepatitis controversial,'6 however, as it is still not known whether the histological stage indicates or predicts ultimate prognosis and liver biopsy carries a recognised morbidity. The only case control study of the longterm outcome of non-A, non-B hepatitis failed to show any difference in the overall mortality between affected and unaffected matched controls.'7 Crucially HCV related liver deaths may take longer to manifest that the 18 year follow up.18 19 Also, the mean age of cases at the time of exposure (49 years) and the mode of transmission are different to that in our study. The age at exposure is lower (mean 24 years) and possibly reflects the most common risk factor of intravenous drug use. Exposure at a younger age would permit more time for histological progression, as another study showed deterioration of 75%/o of repeat liver biopsies with an average follow up of just over two years.20 Therefore a significant mortality resulting from HCV infection among a group of patients exposed to the virus much earlier in adult life cannot be excluded by Seeff's study. '7 The liver biopsy was normal in only two of 42 of our patients. This of two earlier Italian studies showing normal liver histology in a few patients who remain HCV viraemic despite a long period of time since exposure.9 21 While this may represent sampling error inherent in percutaneous liver biopsy, the identification of the HCV genotype and sequence analysis of putative immune epitopes in the viral genome in such patients may aid our understanding of viral persistence and the pathogenic mechanisms in HCV infection.
The distribution of genotypes around the world and the evolutionary analysis of viral sequences suggest that HCV has arrived in Western countries within the past 30 years (personal communication, E Holmes). The commonest risk factor in UK cases seems to be intravenous drug use, which is believed to be on the increase. These facts, together with the length of viral persistence, imply that HCV infection may become an increasing clinical problem if progression occurs commonly. It therefore seems appropriate that continued active assessment and follow up of all infected subjects should be undertaken until the true natural history of this disease is known.22 Liver biopsy should be offered as a routine part of this assessment to all cases, as repeatedly normal liver transaminases do not exclude significant liver involvement in many cases. This will allow for identification of patients suitable for antiviral treatments, reassurance of the patients with normal or minimal disease, and intervention in simple lifestyle measures (for example, reduction in alcohol intake and avoidance of hepatotoxic treatment).
